Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Hoos

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Cancer Immunity|October 21, 2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok, Jeffrey S Weber, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study GroupAlessandro Testori, Jon Richards, Eric Whitman, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
Lancet (London, England)|July 8, 2008
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood, Pramod Srivastava, Ronald Bukowski, et al.
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
The European Regulatory Environment of RNA-Based VaccinesThomas Hinz, Kajo Kallen, Cedrik M Britten, et al.
Annals of the New York Academy of Sciences|June 19, 2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaJedd D Wolchok, F Stephen Hodi, Jeffrey S Weber, et al.
The American Journal of Surgical Pathology|July 20, 2002
Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapyJinru Shia, Satish K Tickoo, Jose G Guillem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4Li Liu, Patrick A Mayes, Stephen Eastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Cancer Immunity|October 21, 2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok, Jeffrey S Weber, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study GroupAlessandro Testori, Jon Richards, Eric Whitman, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
Lancet (London, England)|July 8, 2008
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood, Pramod Srivastava, Ronald Bukowski, et al.
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
The European Regulatory Environment of RNA-Based VaccinesThomas Hinz, Kajo Kallen, Cedrik M Britten, et al.
Annals of the New York Academy of Sciences|June 19, 2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanomaJedd D Wolchok, F Stephen Hodi, Jeffrey S Weber, et al.
The American Journal of Surgical Pathology|July 20, 2002
Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapyJinru Shia, Satish K Tickoo, Jose G Guillem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4Li Liu, Patrick A Mayes, Stephen Eastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Pageof 7